NCT02948413 Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials Status COMPLETED Phase N/A
NCT02942173 CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Status COMPLETED Phase PHASE2/PHASE3
NCT02937675 A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies Status TERMINATED Phase PHASE1/PHASE2
NCT02935153 A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies Status UNKNOWN Phase PHASE1/PHASE2
NCT02933333 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Status UNKNOWN Phase PHASE4
NCT02932280 Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02929615 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Status UNKNOWN Phase PHASE4
NCT02927925 A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type Status COMPLETED Phase PHASE2
NCT02918747 PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage Status UNKNOWN Phase PHASE2
NCT02916316 Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell Status COMPLETED Phase N/A
NCT02909777 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Status COMPLETED Phase PHASE1
NCT02905942 PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation Status UNKNOWN Phase PHASE4
NCT02905916 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Status UNKNOWN Phase PHASE4
NCT02898259 Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Status TERMINATED Phase PHASE1/PHASE2
NCT02889523 Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02885038 Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies Status COMPLETED Phase N/A
NCT02875002 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Status WITHDRAWN Phase PHASE1